1.37 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||1.37 x 1400|
|Ask||1.45 x 1200|
|Day's Range||1.3500 - 1.5079|
|52 Week Range||1.1000 - 5.0500|
|Beta (3Y Monthly)||2.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 15, 2018 - May 21, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.13|
The direct benefit for Immune Design Corp. (NASDAQ:IMDZ), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
In the 26 naïve and relapsed/refractory patients in the randomized trial, the data continue to support the clinical activity of G100, with overall response rates of 46% and 23% in patients receiving a G100 regimen that includes low-dose radiation, with or without pembrolizumab, respectively. Also, disease control was shown in 92% and 85% of patients treated with the G100 regimen with or without pembrolizumab, respectively. In addition, responses appeared to be durable, with overall progression free survival at 11.1 or 7.4 months in patients treated with the G100 regimen with or without pembrolizumab, respectively.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 20, 2018 -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today that.
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in the third quarter of 2018. It expects to have cash to fund operations in 2021.
Immune Design (IMDZ) delivered earnings and revenue surprises of 9.38% and -37.99%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Seattle-based company said it had a loss of 29 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on.
Immune Design (IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced multiple presentations showcasing G100, its potent intratumoral TLR4 agonist, at the annual meeting for the Society for Immunotherapy of Cancer (SITC) being held in Washington D.C. this week. The presentations, which include both clinical and preclinical study data, further support the activity of G100 in follicular lymphoma patients and the potential combinability of G100 with other novel immune-modulatory agents. “These additional positive clinical data continue to support the ability of G100 to trigger a systemic therapeutic effect when injected into a single tumor in follicular lymphoma patients,” said Carlos Paya, M.D., President and Chief Executive Officer of Immune Design.
Immune Design (IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report third quarter 2018 financial results after the close of U.S. financial markets on Tuesday, November 6, 2018. Immune Design management will host a webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 6, 2018 to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers.
NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The layoffs amount to about 20 percent of Immune Design's workforce in Seattle and South San Francisco.
The layoffs amount to about 20 percent of Immune Design's workforce in Seattle and San Francisco.
Immune Design (IMDZ) to discontinue the CMB305 cancer vaccine program and focus on the development of its lymphoma therapy, G100.
Investors need to pay close attention to Immune Design (IMDZ) stock based on the movements in the options market lately.
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Immune Design Corp. plummeted on the news that it is discontinuing a cancer vaccine program. Shares of Histogenics saw gains of over 12% as the company closed on a previously announced underwritten public offering. Immune Design Corp. shares closed down nearly 33.7% on Friday with about 3.3 million shares traded.
Immune Design's stock price dropped more than 30 percent on the decision, which pushes the prospects of FDA approval several years into the future.
Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical device companies made it to 52-week highs. Down In The Dumps (Biotech stocks ...
The big shareholder groups in Immune Design Corp (NASDAQ:IMDZ) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own Read More...